# Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

**Authors:** Mengshi Hu, Tao Yang, Linyu Yang, Lu Niu, Jinbing Zhu, Ailin Zhao, Mingsong Shi, Xue Yuan, Minghai Tang, Jianhong Yang, Heying Pei, Zhuang Yang, Qiang Chen, Haoyu Ye, Ting Niu, Lijuan Chen

PMC · DOI: 10.1038/s41408-024-01058-y · Blood Cancer Journal · 2024-06-26

## Full-text entities

- **Genes:** JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}
- **Diseases:** myeloproliferative neoplasms (MESH:D009369)
- **Chemicals:** Flonoltinib Maleate (-)
- **Mutations:** JAK2V617F

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11208544/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11208544/full.md

---
Source: https://tomesphere.com/paper/PMC11208544